William Y Kim MD
Genitourinary Oncology, Hematologic Oncology
Professor, Medicine and Genetics, University of North Carolina at Chapel Hill School of Medicine
Join to View Full Profile
101 Manning DrChapel Hill, NC 27514
Phone+1 919-966-4996
Fax+1 919-843-5515
Dr. Kim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. William Kim is an oncology specialist based in Chapel Hill, NC, with subspecialties in genitourinary and hematologic oncology. He completed his residency in internal medicine at Beth Israel Deaconess Medical Center and a fellowship in hematology and medical oncology at Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute. Dr. Kim graduated from The Warren Alpert Medical School of Brown University in 1996. His clinical expertise includes conditions such as amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma. He has contributed to numerous publications, including works in prominent journals such as Nature Cancer and The New England Journal of Medicine. Dr. Kim has been involved in clinical trials focusing on prostate cancer and its associated treatments.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1999 - 2002
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1996 - 1999
The Warren Alpert Medical School of Brown UniversityClass of 1996
Certifications & Licensure
NC State Medical License 2006 - 2026
MA State Medical License 1999 - 2006
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification WebCIS, UNC Health Care, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
Clinical Trials
- Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer Start of enrollment: 2009 May 01
- Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy Start of enrollment: 2012 Jun 01
- Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer Start of enrollment: 2013 Oct 01
Publications & Presentations
PubMed
- APOBEC3 promotes squamous differentiation via IL-1A/AP-1 signaling.Michael S Sturdivant, Andrew S Truong, Mi Zhou, Elliott D Toomer, Wolfgang Beckabir
Nature Communications. 2025-12-14 - Impact of renal mass biopsy on decision-making experience for clinical T1 renal masses.Kathryn H Gessner, Allison M Deal, Amir Feinberg, Shannon Myers, Katherine Poulos
The Journal of Urology. 2025-10-28 - Coordinated expression of retained introns and poison exons in renal cell carcinoma.José C Martínez, Mi Zhou, Gilbert Giri, Yi-Hsuan Tsai, Meghan M Rowley
Cell Reports. 2025-08-26
Journal Articles
- VHL Substrate Transcription Factor ZHX2 as an Oncogenic Driver in Clear Cell Renal Cell CarcinomaEric Jonasch, Xian Chen, William Y Kim, W Kimryn Rathmell, Science Magazine
Press Mentions
Renal Cell CarcinomaAugust 28th, 2024- Review Highlights Advances in Kidney Cancer Research and CareAugust 28th, 2024
- Newsworthy from the School of Medicine, Week of August 12 – 19August 18th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
